RxDoctor Payments Data

Amy Allen

Family · Knoxville, TNNPI 1780725168

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.5% of the total across 933 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 6.7% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,668in general payments, 2019–2025

Across 933 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Johnson & Johnson$1K
  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Incyte Corporation$896
  • Amgen$845
  • plus $14K from 54 others

What the payments were for

  • Food & beverage$19,53695%
  • Education$1,1325%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)60$1,379
Johnson & Johnson39$1,151
Novartis55$1,067
E.r. Squibb & Sons, L.L.C.49$1,044
Incyte Corporation33$896
Amgen39$845
Genentech USA, Inc.42$823
Sanofi31$784
Seagen Inc.34$767
Pfizer38$760
Merck33$726
Astellas Pharma US Inc32$717
Gilead(2 entities)29$705
Bristol Myers Squibb42$685
Regeneron Healthcare Solutions, Inc.23$597
Eisai Inc.30$591
AbbVie24$554
Daiichi Sankyo Inc.25$518
GSK23$492
Bayer21$411
Takeda Pharmaceuticals U.S.A., Inc.18$405
Lilly USA, LLC19$388
Karyopharm Therapeutics Inc.13$368
Pharmacyclics LLC, An Abbvie Company16$273
Exelixis Inc.9$221
AVEO Pharmaceuticals, Inc.6$205
Deciphera Pharmaceuticals Inc.9$204
Jazz Pharmaceuticals Inc.5$171
Morphosys, US Inc.6$156
Beigene USA, Inc.7$154
Genmab U.S., Inc.7$147
Boehringer Ingelheim7$146
Tersera Therapeutics LLC7$138
Ipsen Biopharmaceuticals, Inc6$134
Array Biopharma Inc6$123
Sobi, Inc6$122
EMD Serono, Inc.6$119
Rigel Pharmaceuticals, Inc.6$112
Mirati Therapeutics, Inc.4$107
Beone Medicines USA, Inc.4$90
Myriad Genetic Laboratories, Inc.5$89
Pharmacosmos Therapeutics Inc.4$84
Novocure Inc.5$83
Sanofi-aventis U.S. LLC1$83
Stemline Therapeutics Inc.3$74
Taiho Oncology, Inc.4$73
Geron Corporation3$72
Blueprint Medicines Corporation3$70
Servier Pharmaceuticals LLC3$69
Myovant Sciences Inc.4$68
G1 Therapeutics, Inc.3$68
ADC Therapeutics America, Inc.3$64
Epizyme, Inc.3$46
Janssen Scientific Affairs, LLC1$35
Caris MPI, Inc.1$33
Puma Biotechnology, Inc.2$33
Immunogen, Inc.1$29
Secura Bio, Inc.2$27
Syndax Pharmaceuticals, Inc.1$27
TG Therapeutics, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,668 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$16,410
Medicare patients
43
Services billed
255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$19,827
XareltoRivaroxaban17$10,932
Oxycodone Hcl66$1,507
Ondansetron OdtOndansetron48$1,039
Megestrol Acetate13$766
Letrozole26$606
Morphine Sulfate ErMorphine Sulfate18$503
Gabapentin37$463
Prochlorperazine Maleate31$432
Tramadol Hcl19$334
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen13$285
Lorazepam37$234
Ondansetron Hcl12$181
Zaleplon12$146
Potassium Chloride14$145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$760$19,82728 claims
Johnson & JohnsonXarelto$1,151$10,93217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →